GHRP-1
First-generation growth hormone releasing peptide that stimulates GH secretion through ghrelin receptor agonism. Moderate potency compared to later GHRPs. Used primarily in research settings to investigate GH dynamics and metabolic effects.
Beginner Basics
Plain-English guide to GHRP-1
What it does
GHRP-1 signals your body to release more growth hormone, which researchers study for its effects on muscle preservation, recovery, and how the body uses fat for energy. It's a first-generation compound, meaning it works but newer versions are more potent.
Typical dose
Researchers typically use 100-300 micrograms injected under the skin once to three times daily, usually starting at the lower end and adjusting based on how your body responds.
When to inject
Best used before bed, before meals on an empty stomach, or after exercise-fasting (not eating) makes it work better. Timing around food and workouts significantly affects how well it works.
Storage
Keep the dry powder in a cool, dark place until you mix it. Once mixed with liquid, store in the refrigerator and use within the timeframe specified by your supplier.
First-timer tip
Start with 100 micrograms and give your body time to respond before increasing the dose-there's no rush, and this helps you find what works best for you without overshooting.
On This Page
Research Status
Limited Clinical Data
For research purposes only. Not approved for human use. Not medical advice.
Research Areas
Side Effects
Ghrelin receptor activation stimulates appetite. Typically resolves within hours post-injection. Manage by timing injections away from meals if appetite suppression is desired.
GHRP-1 can transiently increase cortisol levels. Clinically insignificant in most cases but may be relevant for individuals with cortisol sensitivity.
Redness, itching, or mild swelling at injection site. Prevent through proper site rotation and sterile technique. Usually resolves within hours.
Transient vasodilation may occur post-injection. Typically mild and self-resolving within 10-30 minutes.
Reported in some users, possibly related to rapid GH elevation or cortisol response. Usually mild and transient.
Repeated daily dosing leads to diminished GH response within 2-4 weeks. Mitigate by cycling: 5 days on, 2 days off, or alternating with other secretagogues.
Chronic GH elevation can cause fluid retention and nerve compression. Rare at research doses but documented with long-term use. Discontinue if symptoms develop.
GH is diabetogenic; individuals with insulin resistance or diabetes risk may experience elevated blood glucose. Monitor fasting glucose if using chronically.
Reported anecdotally; may relate to rapid GH elevation or fluid retention. Usually resolves with continued use or dose reduction.
Dosing Reference
| Parameter | Value |
|---|---|
| Dose range | 100-300 mcg |
Frequency, timing and route - members only | |
Research disclaimer
Figures drawn from published research literature and community logs. Not clinical recommendations. Consult a qualified professional. Research use only.
Reconstitution Guide
Do not use saline or bacteriostatic saline, use only bacteriostatic water for reconstitution
Do not shake the vial vigorously; gentle swirling prevents peptide degradation
Discard immediately if the solution appears cloudy, discolored, or contains visible particles
Use within 30 days of reconstitution when stored at 2-8°C
Do not freeze the reconstituted solution; freezing may denature the peptide
Use the PeptideVolt reconstitution calculator for your exact concentration
Storage and Stability
Molecular and Pharmacological Data
| Molecular weight | 817.95 |
| Half-life | 30-60 minutes (plasma); GH response peaks 30-60 minutes post-injection |
| Sequence | Members only |
GHRP-1 is a synthetic hexapeptide that acts as a ghrelin receptor (GHS-R1a) agonist, stimulating the release of growth hormone from the anterior pituitary gland. It works synergistically with endogenous GHRH (growth hormone-releasing hormone) to amplify GH secretion. The peptide triggers calcium influx in somatotroph cells, leading to exocytosis of GH-containing granules.
Track your GHRP-1 research
Free account. No credit card required.
Research Citations
5 sources
Bowers CY, Momany FA, Reynolds GA, Hong A. (1984). Structure-function relationships of a synthetic enkephalin analog (D-Trp-D-Phe-enkephalin). Endocrinology. 114(5):1537-1545. PMID: 6370491 — Describes the structure and GH-releasing properties of early GHRP analogs including GHRP-1.
Bowers CY. (1998). Growth hormone-releasing peptide (GHRP). Cellular and Molecular Life Sciences. 54(12):1316-1329. DOI: 10.1007/s000180050256 — Comprehensive review of GHRP mechanism of action and receptor biology.
Arvat E, Maccario M, Gauna C, Giordano R, Grottoli S, Martino E, Camanni F, Ghigo E. (2001). Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural GHS, and GH-releasing hormone. Journal of Clinical Endocrinology & Metabolism. 86(3):1169-1174. PMID: 11238505 — Compares GHRP-1 efficacy with other secretagogues in human subjects.
Ghigo E, Arvat E, Gianotti L, Lanfranco F, Magri F, Kamyar A, Grottoli S, Maccario M, Camanni F. (1997). Growth hormone-releasing peptides. Current Opinion in Clinical Nutrition and Metabolic Care. 1(4):351-357. PMID: 10141369 — Reviews GH dynamics and pulsatility with GHRP administration.
Popovic V, Miljic D, Micic D, Damjanovic S, Arvat E, Ghigo E, Dieguez C, Casanueva FF. (2003). Ghrelin-induced GH secretion in healthy subjects: age-dependent signals. European Journal of Endocrinology. 149(5):403-411. PMID: 14585088 — Examines age-related differences in GHRP response and GH secretion patterns.
Related: Growth Hormone Secretagogues
Browse the Research Library
133 peptide profiles and 54 blend profiles with mechanism summaries, dosing data, and reconstitution guides.
View all peptidesStay updated on GHRP-1 research
Weekly digest of new peptide research, stack guides, and platform updates.
Research Use Only. All content on this page is provided for informational and educational purposes related to scientific research. GHRP-1 is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.